SZABO SCANDIC

Part of Europa Biosite

# Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

## Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

## Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand


**SZABO-SCANDIC HandelsgmbH**

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

# PRODUCT INFORMATION

## LY2828360

*Item No. 26791*

| | |
|---|---|
| **CAS Registry No.:** | 1231220-79-3 |
| **Formal Name:** | 8-(2-chlorophenyl)-2-methyl-6-(4-methyl-1-piperazinyl)-9-(tetrahydro-2H-pyran-4-yl)-9H-purine |
| **MF:** | $C_{22}H_{27}ClN_6O$ |
| **FW:** | 426.9 |
| **Purity:** | ≥98% |
| **UV/Vis.:** | $\lambda_{max}$: 219, 284 nm |
| **Supplied as:** | A crystalline solid |
| **Storage:** | -20°C |
| **Stability:** | ≥2 years |




*Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.*

### Laboratory Procedures

LY2828360 is supplied as a crystalline solid. A stock solution may be made by dissolving the LY2828360 in the solvent of choice. LY2828360 is soluble in the organic solvent chloroform, which should be purged with an inert gas, at a concentration of approximately 30 mg/ml.

### Description

LY2828360 is a cannabinoid (CB) receptor 2 agonist ($K_i$ = 40.3 nM).[1] It selectively activates $CB_2$ over $CB_1$ in a GTPγS binding assay ($EC_{50}$s = 20.1 and >100,000 nM, respectively). It reduces differences in hind paw weight bearing between monoiodoacetic acid- and saline-injected knees in a rat model of knee joint-related chronic pain induced by monoiodoacetic acid (MIA) when administered at doses greater than or equal to 0.1 mg/kg. LY2828360 dose-dependently reduces mechanical and cold allodynia induced by paclitaxel (Item No. 10461) in mice and prevents development of morphine tolerance when administered at dose of 3 mg/kg per day for 12 days.[2] It also reduces paclitaxel-induced allodynia in morphine-tolerant mice.

### References


1. Hollinshead, S.P., Tidwell, M.W., Palmer, J., *et al.* Selective cannabinoid receptor type 2 ($CB_2$) agonists: Optimization of a series of purines leading to the identification of a clinical candidate for the treatment of osteoarthritic pain. *J. Med. Chem.* **56(14)**, 5722-5733 (2013).
2. Lin, X., Dhopeshwarkar, A.S., Huibregtse, M., *et al.* Slowly signaling G protein-biased $CB_2$ cannabinoid receptor agonist LY2828360 suppresses neuropathic pain with sustained efficacy and attenuates morphine tolerance and dependence. *Mol. Pharmacol.* **93(2)**, 49-62 (2018).





**CAYMAN CHEMICAL**
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
**PHONE:** [800] 364-9897
[734] 971-3335
**FAX:** [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM